Efficacy and Biomarker Results for Pembrolizumab in Soft Tissue and Bone Sarcomas

The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of patients with relapsed/refractory osteosarcoma.

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.